Loading...
•
Jun 30, 2023
Nkarta Q2 2023 Earnings Report
Nkarta reported financial results for the second quarter ended June 30, 2023.
Key Takeaways
Nkarta reported a net loss of $33.3 million for the second quarter of 2023, with cash and cash equivalents of $302.2 million as of June 30, 2023. The company's cash runway is anticipated to fund operations into 2025. Clinical updates are planned for NKX019 in the second half of 2023 and NKX101 in the first half of 2024.
NKX101 clinical update highlights encouraging antileukemic activity in patients with AML using fludarabine/cytarabine (Flu/Ara-C) lymphodepletion regimen.
NKX019 clinical data presented at EHA 2023 and ICML 2023 meetings.
Clinical updates planned for NKX019 in the second half of 2023 and NKX101 in the first half of 2024.
Cash and cash equivalents of $302.2 million on June 30, 2023; cash runway anticipated to fund operations into 2025.
Forward Guidance
Nkarta expects its current cash and cash equivalents will be sufficient to fund its current operating plan into 2025.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...